证券之星消息，12月29日化学制药板块较上一交易日下跌1.52%，宏源药业领跌。当日上证指数报收于 3965.28，上涨0.04%。深证成指报收于13537.1，下跌0.49%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301075 | 多瑞医药 | 56.58 | 9.89% | 3.09万 | | 1.67亿 | | 688176 | 亚虹医药 | 11.57 | 4.61% | 15.98万 | | 1.83亿 | | 002099 | 海翔药业 | 6.17 | 3.35% | 51.94万 | | 3.23亿 | | 600624 | ST复华 | 5.42 | 2.46% | 13.83万 | | 7539.02万 | | 300401 | 化园生物 | 15.39 | 2.33% | 26.30万 | | 4.03亿 | | 600513 | 联环药业 | 18.63 | 1.80% | 14.30万 | | 2.67亿 | | ...

Core Viewpoint - Boteng Co., Ltd. has successfully passed the EU Qualified Person (QP) audit, indicating that its quality management system meets EU GMP standards and can provide international standard formulation development and production services to global clients [1] Group 1: Audit and Compliance - Boteng Pharmaceuticals, a wholly-owned subsidiary of Boteng Co., Ltd., received a compliance statement from the EU Qualified Person [1] - The audit was conducted based on EU GMP Guidelines EudraLex Volume 4, EU Clinical Trial Regulation (536/2014), and GMP for IMP guidelines [1] - The audit scope included quality management, production management, facilities, material systems, and packaging and labeling systems for injectable, oral solid, and non-sterile semi-solid formulations [1] Group 2: Implications for Business - The successful QP audit signifies that Boteng Pharmaceuticals can now offer customized formulation development and production services that comply with international standards [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of Hydroxocobalamin injection, indicating progress in its drug development pipeline [1] Group 1: Regulatory Approval - The company received the clinical trial approval notice for Hydroxocobalamin injection on December 25, 2025, after the acceptance notice on October 22, 2025 [1] - The approval is significant for the treatment of metabolic disorders in children with methylmalonic acidemia, with or without homocystinuria [1] Group 2: Research and Development Investment - The total R&D investment for Hydroxocobalamin injection has reached RMB 13.0581 million (unaudited) as of the date of the announcement [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | 2025-12-29 | 002923 | 润都股份 | 12.10 | 69.57 | 841.80 国金证券股份有限 | 国金证券股份有限 | | | | | | | 公司成都高新区交 | 公司成都高新区交 | | | | | | | 子大道证券营业部 | 子大道证券营业部 | 12月29日，润都股份大宗交易成交69.57万股，成交额841.8万元，占当日总成交额的19.95%，成交价12.1元，较市场收盘价 12.11元折价0.08%。 ...

博腾股份公告，全资子公司重庆博腾药业有限公司近日获得欧盟质量受权人签发的符合性声明，顺利通 过欧盟QP审计。 ...

证券日报网讯12月29日，浙江震元（000705）在互动平台回答投资者提问时表示，目前公司生产的组氨 酸争取逐步替代韩国、日本的产品。 ...

Group 1 - The clinical trial for Amoxicillin capsules by Zhejiang Anglikang Pharmaceutical Co., Ltd. has been initiated, focusing on the bioequivalence study in healthy Chinese subjects [1] - The trial is designed as a single-center, open-label, randomized, single-dose, two-period, two-sequence, and crossover study, with a clinical trial registration number of CTR20255192 [1] - The primary objective is to evaluate the pharmacokinetics of the test formulation compared to the reference formulation under fasting conditions, while the secondary objective assesses the safety of both formulations [1] Group 2 - The trial's primary endpoints include Cmax, AUC0-t, AUC0-∞, vital signs, physical examinations, 12-lead ECG, clinical laboratory tests, and adverse events, evaluated 12 hours post-administration [2] - Secondary endpoints consist of Tmax, t1/2, λz, AUC_%Extrap, Vd/F, CL/F, F, along with the same safety assessments as primary endpoints, evaluated until the end of follow-up [2] - The current status of the trial is ongoing, with a target enrollment of 24 participants [3]

Core Viewpoint - The article discusses various companies' recent announcements regarding stock price fluctuations, operational updates, and strategic partnerships, highlighting potential investment opportunities and risks in the market. Group 1: Company Announcements - Aerospace Development reported a revenue of 1.697 billion yuan for the first three quarters of 2025, with a significant increase attributed to ship deliveries, while its subsidiary's revenue contribution remains below 1% [3] - Victory Energy announced that it may apply for a trading suspension if its stock price continues to rise, indicating potential risks for investors [4] - Jia Mei Packaging also warned of possible trading suspension due to significant stock price deviations from its fundamentals, urging investors to be cautious [5][6] - Fenglong Co. stated that its acquirer, UBTECH, has no plans to change its main business or conduct significant asset transactions in the next 12 months [7] - ST Huluwa is under investigation by the China Securities Regulatory Commission for information disclosure violations, but its operations continue normally [8] Group 2: Project Updates - Yijing Optoelectronics announced delays in its photovoltaic project in Anhui due to industry-wide capacity mismatches, leading to a halt in production and potential financial liabilities [9] - Tongyu Communication cautioned about the risks of irrational market speculation following a significant stock price increase [10] - Junda Co. clarified that its strategic cooperation with Shangyi Optoelectronics will not have a major impact on its current financial performance due to the preliminary nature of the agreement [12] Group 3: Strategic Partnerships and Acquisitions - Hengrui Medicine signed an exclusive licensing agreement with Hansoh Pharmaceutical, which includes a 30 million yuan upfront payment and potential milestone payments totaling up to 190 million yuan [13] - Tongye Technology plans to acquire a 91.69% stake in Beijing Silingke Semiconductor Technology for 561 million yuan, focusing on power IoT communication chips [14] - ST Lutong intends to apply for the removal of risk warnings after a shareholder's commitment to repay funds misappropriated by the actual controller [15] Group 4: New Contracts and Market Expansion - Wangfujing won a bid for the Beijing Capital International Airport duty-free project, with a guaranteed operating fee of 113 million yuan for the first year and a sales commission of 5%, marking its entry into a major international hub [17]

Group 1 - Aerospace Development's subsidiary, Chongqing Tianmu Satellite Technology Co., Ltd., accounted for less than 1% of the company's total revenue in the first three quarters of 2025 [2] - Aerospace Development achieved a revenue of 1.697 billion yuan in the first three quarters of 2025, an increase attributed to ship deliveries [2] - The company focuses on aerospace defense information technology, continuing to develop blue army systems and new-generation communication and command equipment [2] Group 2 - Victory Energy announced that if its stock price continues to rise, it may apply for a trading suspension for verification [3] - Jia Mei Packaging stated that its stock price has significantly deviated from its fundamentals, and it may also apply for a trading suspension if prices rise further [4] - Fenglong Co. confirmed that there are no plans to change its main business or make significant adjustments in the next 12 months [5] Group 3 - ST Huluwa announced that the company and its chairman are under investigation by the China Securities Regulatory Commission for information disclosure violations [6] - Yijing Optoelectronics is facing challenges in its photovoltaic project in Quanjiao County, with a potential investment agreement termination and a demand for repayment of 140 million yuan [7] - Tongyu Communications warned of risks related to market sentiment and irrational speculation due to significant stock price fluctuations [8] Group 4 - Junda Co. stated that its strategic cooperation agreement with Shangyi Optoelectronics will not have a significant impact on its current operating performance [9] - Heng Rui Pharmaceutical signed an exclusive licensing agreement with Hansoh Pharmaceutical, with potential milestone payments totaling up to 190 million yuan [10] - Tongye Technology plans to acquire 91.69% of Beijing Silingke Semiconductor Technology Co., Ltd. for 561 million yuan [11] Group 5 - ST Lutong intends to apply for the removal of other risk warnings after a shareholder repaid 10.2254 million yuan in funds [12] - Wangfujing won the bid for the Beijing Capital International Airport duty-free project, with a guaranteed operating fee of 113 million yuan for the first year [14]

Major Events - Fenglong Co., Ltd. announced that after the change of control, the company will continue to focus on its original business, with no plans for significant adjustments or asset restructuring in the next 12 months [1] - The company aims to optimize management and resource allocation to enhance operational and profitability capabilities, although uncertainties remain regarding future business cooperation [1] Financial Transactions - Tongyi Technology plans to pay 561 million yuan to acquire 91.69% of Beijing Silin Technology Co., Ltd. through a cash transaction [9] - Hengrui Medicine signed an exclusive licensing agreement with Hansoh Pharmaceutical for the SHR6508 project, which includes an upfront payment of 30 million yuan and potential milestone payments up to 190 million yuan [2] Operational Updates - Yijing Optoelectronics received a hearing notice from the Quanjiao Economic Development Zone regarding potential administrative decisions due to failure to fulfill prior agreements related to a solar project [3] - China Shenhua's subsidiary successfully completed a 168-hour trial run of its new power generation unit, which will enhance regional power supply stability [5][6] Strategic Developments - Kingfisher Co., Ltd. won a bid for the duty-free project at Beijing Capital International Airport, which could enhance its market presence, although the project is still subject to contract finalization [10] - Jun Da Co., Ltd. stated that its strategic cooperation with Shangyi Optoelectronics will not significantly impact current operating performance due to the preliminary nature of the agreement [4] Revenue Insights - Aerospace Development reported a revenue of 1.697 billion yuan for the first three quarters of 2025, with a significant contribution from ship deliveries, while its satellite operations accounted for less than 1% of total revenue [7]